Blockchain Registration Transaction Record
Lexaria Bioscience Begins GLP-1 Study, Files New Patents
Lexaria Bioscience announces start of Animal Study #1 evaluating DehydraTECH-GLP-1 and CBD formulations, files three new patents for SNAC alternatives, and receives Australian patent for hypertension treatments.
This news matters because Lexaria's exploration of SNAC alternatives could disrupt the GLP-1 drug market, which includes blockbusters like Rybelsus and Wegovy. If successful, DehydraTECH formulations may offer improved brain biodistribution, potentially enhancing efficacy and reducing side effects for diabetes and obesity treatments. The new patent on hypertension therapies also broadens Lexaria's pipeline, impacting patients seeking more effective oral drug delivery options.
| Blockchain | Details |
|---|---|
| Contract Address | 0xeA2912a8DA1CD48401b10cB283585874d98098F4 |
| Transaction ID | 0xe6fb2b0a181c0e8fbc611a2671fb1ca6ac16c2c29d4cc84f9ef74cb28f2c1e6a |
| Account | 0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20 |
| Chain | polygon-main |
| NewsRamp Digital Fingerprint | ovalLgo7-8464d7d47c05346ea5e9db8f1c18cd0f |